• Carlos Izaias Sartorão-Filho, Mariana Costa Zoqui, Douglas Otomo Duarte, Edy Alyson Ribeiro, Vinicius César Queiroz Bisetto, Lara Escobar Gavião Cachoni, Ana Luísa Varrone Sartorão, Diogo Coutinho Terribile, Beatriz Balsimelli de Mello, Carlos Izaias Sartorão-Neto, and Roberto de Mello.
• MD, PhD. Professor of Medicine, Fundação Educacional do Município de Assis (FEMA), Assis (SP), Brazil.
• Sao Paulo Med J. 2022 Jan 1; 141 (3): e202295e202295.

BackgroundHesitation and refusal to take a second dose of the vaccine for coronavirus disease 19 (COVID-19) are prevalent.ObjectivesWe aimed to identify predictive factors for hesitation or refusal and describe groups with higher rates of vaccine hesitancy.Design And SettingA cross-sectional study in Assis City, Brazil.MethodsThe study included adults who passed the due date for taking the COVID-19 second dose vaccine. Participants were recruited in December 2021 using a mobile-based text message. Sociodemographic and clinical data and reasons for hesitance were collected. The outcome was the attitude towards completing the recommended second dose of the vaccine. Bivariate and multivariate Poisson analyses were performed to determine the adjusted predictors.ResultsParticipants between 30-44 years of age had a 2.41 times higher prevalence of hesitation than those aged 18-29 years. In addition, people who had adverse events or previously had COVID-19 had 4.7 and 5.4 times higher prevalences of hesitation, respectively (P value < 0.05).ConclusionWe found a significant group of adults aged between 30-44 years who refused the second dose of the COVID-19 vaccine. Furthermore, those who reported adverse effects after the first dose and those who had COVID-19 previously were a significant group for refusal.

19 keywords...

hide…